First Investment: 2021
Shennon has built an ultra-high-throughput profiling engine that allows it to analyze millions of immune cells on the single-cell level, searching for rare receptors and other targets that will help the company create more effective immunotherapies for solid tumors.
News & Insights
Explore Companies
Radionetics Oncology
Discovering more precise ways to deploy radiopharmaceuticals against solid tumors
DVLP Medicines
Creating a software co-pilot for drug development and a new marketplace for investors and outsourced R&D and manufacturing
Noetik
Using self-supervised machine learning to map the circuit diagram of tumor biology and develop new immunotherapies for cancer
Solu Therapeutics
Advancing precision medicine by combining the efficacy of antibodies with the binding ability of small molecules